"The first human trial of a pioneering personalised cancer treatment developed at Oxford University will begin this week, with the potential to tackle a wide range of late-stage cancers.
"A major challenge in drug development is that all cancer patients respond differently to treatment, making it difficult to know how best to treat each patient. For the first time, a phase I trial in Oxford will investigate not only a new drug, called CXD101, but also a new test to predict which patients could be successfully treated by this class of drug."
Editor's Note: This clinical trial uses molecular testing to determine whether patients will benefit from the treatment being tested. Not all clinical trials take this important step. Read more about this issue.